BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€526.00FzxnkyCztlwtny

BioMerieux's First Half Tracks Our (High) Expectations; BioFire Still Firm's Sole Growth Driver

Narrow-moat BioMerieux reported first-half results, which followed the firm’s pre-announcement on July 9 of nearly 16% sales growth through the first two fiscal quarters. With sales and income tracking close to our full-year expectations, there was little in the earnings release that surprised us, and we are maintaining our EUR 65 fair value estimate.

Sponsor Center